Skip to content
GPCR·Nasdaq·US

Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for chronic metabolic and cardiopulmonary diseases, with a pipeline centered on GPCR-targeted drug candidates. Its business is primarily research and development, and it remains largely pre-revenue.

Recent Activity

Updated Oct 24, 2026
–Structure Therapeutics announced on October 19, 2026 that it will make multiple presentations at ObesityWeek 2026.

Past updates are part of the Pro plan.

Thematic Position

GPCR

Relationship Groups

Suppliers1
Partners1
Licensing1
Competitors9

Relationship details are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

export controlnational security reviewentity list
BIOSECURE Act under 2026 NDAA restricts contracting with Chinese biotech firms
SEC 10-QMay 7, 2026

The full regulatory passage is part of the Pro plan.

16 more · Regulatory and geopolitical insights are part of the Pro plan.